Mayo Clinic and Stanford Medicine developed a first blood test intended to chart tumor “neighborhoods” and predict therapy response by analyzing the microenvironment surrounding cancer cells. The platform goes beyond conventional liquid biopsy approaches by aiming to decode spatial biology from blood. The work focuses on translating tumor microenvironment signals into actionable biomarkers for clinicians, with the test designed to help identify likely responders and guide precision oncology decisions. The development adds to a growing wave of minimally invasive diagnostics that attempt to infer microenvironmental state from circulating samples, potentially shifting how trials and treatment selection are informed.